Business
PARSORTIX ENABLES STUDY OF CANCER PROGRESSION
PARSORTIX ENABLES STUDY OF CANCER PROGRESSION.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n\n\n\n\n\nFor immediate release\n\n\n8 July 2025\n\n\n\n\n \nANGLE plc (\"the Company\")\n \nPARSORTIX SYSTEM enableS the study of CANCER PROGRESSION\n \nNew publication in Nature Genetics using Parsortix identifies CTC clusters as promising targets to stop the spread of cancer \n \n \nANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce the publication of a peer-reviewed article in Nature Genetics by Professor Nicola Aceto's team at ETH Zurich, Switzerland. The study utilised the Parsortix® system to investigate the genetic diversity of CTC clusters.\n \nUnderstanding the genetic diversity of CTC clusters is of clinical importance because these cells are the precursors of progressive disease and metastasis. Cancer is a highly dynamic process, and cells are known to diversify over time due to treatment selection pressure and the accumulation of genetic changes. This leads to the emergence and expansion of new subclones with distinct characteristics and varying abilities to survive and proliferate. This process is crucial because it drives cancer development, progression, resistance to therapy, and relapse and can help in understanding how to develop effective cancer treatments.\n \nThis publication provides evidence of genetic diversity in CTC clusters in breast cancer patient samples and preclinical mouse models. It includes the finding that some mutations were exclusive to specific cells within CTC clusters that could therefore be missed by a tissue biopsy. The research in mouse models reports a higher prevalence of CTC clusters in high-complexity tumours, with large CTC clusters associated with higher genetic diversity.\n \nThe genetic diversity reported in this publication points to CTC clusters as key contributors to genetic diversity in metastasis. The authors believe that genetic diversity within CTC clusters enhances their metastatic capability by increasing therapy resistance opportunities, evasion of immune cell attack, as well as adaptability and survival at a metastatic site. CTC clusters are therefore important targets to stop the spread of cancer given these are up to 100 times more metastatic than individua...